13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 4 of 7 – SEC Filing

1

Names of Reporting Persons.

RA Capital Healthcare Fund, L.P.

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
3 SEC Use Only
4

Source of Funds (See Instructions):

WC

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

[ ]

6 Citizenship or Place of Organization.     Delaware

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7 Sole Voting Power     0
8 Shared Voting Power      4,018,603
9 Sole Dispositive Power     0
10 Shared Dispositive Power  4,018,603
11

Aggregate Amount Beneficially Owned by
Each Reporting Person

4,018,603

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     [ ]
13

Percent of Class Represented by Amount
in Row (11)

17.5%3

14

Type of Reporting Person (See Instructions)

PN (Limited Partnership)

_________________

3 Represents 2,256,071 shares
of the Common Stock of the Issuer and 1,762,532 shares of the Common Stock issuable upon conversion of Preferred Stock attributable
to the Fund which constitute approximately 17.47% of the class outstanding. The percentage calculation assumes that there are
currently 20,848,503 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-Q for the quarterly
period ended September 30, 2017 as filed with the SEC on November 2, 2017.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)